{'fraction_non_alphanumeric': 0.044232922732362824, 'fraction_numerical': 0.0335946248600224, 'mean_word_length': 4.498461538461538, 'pattern_counts': {'":': 0, '<': 4, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Abstract 17144: Cardioprotective Effect of Beta Blockers in Patients With Breast Cancer Undergoing Chemotherapy and Radiation Therapy: Is It a Myth or Reality?


 Background:
 Breast cancer is the leading cause of cancer in women worldwide. Cardiotoxicity is a common complication of anthracycline based regimens. It has been suggested that use of beta blockers (BB) may have cardioprotective effect in patients with breast cancer undergoing therapy.
 
 
 Methods:
 A systematic search of 3 electronic databases was performed for all randomized clinical trials between 1990 and 2018 comparing BB and placebo in patients with breast cancer undergoing chemotherapy. Primary outcome was change in left ventricular ejection fraction (LVEF) , secondary outcome was change in LV diastolic function measured as difference in early (E) to late (A) ventricular filling velocities (E/A ratio). We used Cohen method for this meta-analysis.
 
 
 Results:
 Total of 6 studies evaluating 614 females, with mean age of 49 (±7) years were included. These patients were receiving anthracyclines with or without transtuzumab over weighted mean follow up of 8 (±3) months. There was a smaller LVEF decline in patients treated with BB compared to placebo with standardized mean difference (SMD) of 0.34% (0.18%-0.5%), p<0.01 and significant heterogeneity I
 2
 86%, p<0.01(Figure 1). There were only 3 studies reporting on e/a ratio. There was a significantly lower decline in e/a with BB therapy , SMD of 0.46 (0.23-0.7), p<0.01, with high heterogeneity I
 2
 85%, p<0.01 (Figure 2).
 
 
 Conclusion:
 Beta blockers can preserve left ventricular systolic and diastolic function in patient with breast cancer undergoing chemotherapy. Observed high heterogeneity indicates the need for larger trials.
 
 
 
